Rouen, France, May 04, 2021 – Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. The Percutaneous Coronary Interventions (PCI) were performed on April 8 and 13 by Prof. Stefan Verheye, a recognized and highly experienced interventional cardiologist at ZNA Middelheim hospital in Antwerp, and his team.  Robotic-assisted PCI has never been done before in this country.

R-One is…

Rouen, France, January 13, 2021 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in France – spanning 75 miles (120 km) between the two locations. The procedure is the first of its kind…

Rouen, France, December 14, 2020 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces that it has appointed Chantal Le Chat as an independent member of the Strategic Committee.

Chantal boasts 35 years of skill and know-how built up while working a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including…

Rouen, France, November 2, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces creation of the joint venture with MicroPort Scientific Corporation ‘MicroPort’, through ‘MedBot’, its MicroPort MedBot (Shanghai) Co. Ltd subsidiary. This strategic partnership will enable the commercialization in China of its first robotic-assisted platform, R-One™. Both companies will also carry out research and development activities as agreed per the terms of the investment announced in April…

Rouen, France, April 29, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has secured €40 million ($43M) in a series C round of financing. This was led by MicroPort Scientific Corporation (HKG:853), a major listed industrial player in the cardiovascular field, with participation from institutional investors (Zhejiang Silk Road Fund, Luxembourg CLIIF managed under TUS-Holdings, CS Group and Anaxago) as well as existing Robocath investors (1).

Rouen, France, December 16, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed six robotic coronary angioplasties with R-One™, a first for the continent of Africa. These Percutaneous Coronary Interventions (PCI) were performed by Dr Faizel Lorgat, an interventional cardiologist at the Netcare Christiaan Barnard Memorial Hospital, Cape Town, as part of a distribution agreement with Vertice MedTechGroup. These procedures will lead to the…

Rouen, France, February 26, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has obtained CE certification for its R-One™ robotic device. As a result, it can begin commercialization in Europe and the Middle East.

R-One™ is the first European robotic solution to obtain the CE mark in the field of interventional cardiology. The robot assists interventional cardiologists in stenting (angioplasty) by enabling precision technologies that…

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that the Medical Training and Testing Center (MTC) in Rouen will use its R-One™ robot for future training. Founded in 2017, the MTC is a new center dedicated to training healthcare professionals in a number specialties, with special focus on new technologies.

The R-One™ robot at the MTC will enable the training of future potential users and ensure optimal use by…

100% technical success and no MACE[1] scored in first pre-clinical randomized trial

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

The prospective, randomized, controlled, multi-operator study evaluated the efficacity and safety of the robotic system compared to a manual procedure. Results showed that…

Rouen, January 30, 2018 – Robocath, a company that conceives and develops cardiovascular robotic systems for the treatment of vascular diseases, announces today the creation of its medical advisory board including global experts and recognized leaders in interventional cardiology.

This committee will help define the clinical strategy of the company and more broadly contribute to the development of future generations of Robocath’s robotic system products.

Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased…